A5003030864- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Occupational and environmental lung diseases
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Pleural and Pulmonary Diseases
- Prostate Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Brain Metastases and Treatment
- Testicular diseases and treatments
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
National Health and Medical Research Council
2016-2025
The University of Sydney
2016-2025
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
2015-2025
University of British Columbia
2024
Cooperative Trials Group for Neuro-Oncology
2016-2022
Bayer (United States)
2021
Vancouver Clinic
2021
Clinical Trials New Zealand
2021
Astellas Pharma (United Kingdom)
2021
Sanofi (France)
2021
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, or without early docetaxel, will improve metastatic, hormone-sensitive cancer.In this open-label, randomized, phase 3 trial, we assigned patients receive suppression plus either open-label a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point...
Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices International Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets patients with aberrations their tumor that could be targeted currently available therapies.
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts women with advanced endometrial cancers (AEC)-mismatch repair proficient (pMMR) and mismatch deficient (dMMR).A multicenter phase study was performed AEC pMMR tumor progressing after one three lines chemotherapy dMMR zero chemotherapy. Mismatch status based on immunohistochemistry expression. All received durvalumab 1500 mg given every 4 weeks until progression or unacceptable...
Abstract Background Temozolomide offers minimal benefit in patients with glioblastoma unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose) polymerase (PARP) inhibitor, acts synergistically radiation and temozolomide. Methods VERTU was multicenter 2:1 randomized phase II trial newly diagnosed MGMT-unmethylated promotor status. The experimental arm consisted of...
5501 Background: Deficient DNA mismatch repair (dMMR) occurs in approximately 15% of AEC and is associated with a high tumour mutation burden. Expression PD-1 PD-L1 has been reported up to 90% ECs, including those proficient (pMMR). We report here preliminary results PHAEDRA, single-arm phase 2 trial designed determine the activity single-agent durvalumab, an antibody PD-L1, cohorts women AEC. Methods: Participants (pts) had pMMR progressing after 1-3 lines chemotherapy, or dMMR 0-3 were...
We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects health-related quality life (HRQL).HRQL was assessed with the European Organisation for Research and Treatment Cancer core quality-of-life questionnaire QLM-PR25 at weeks 0, 4, 12, then every 12 until progression. Scores from week 4 156 were analyzed repeated measures modeling calculate group means...
LBA294 Background: AGOC has limited options after second-line therapy. Regorafenib (Rego), an oral multi-targeted tyrosine kinase inhibitor (TKI) targeting angiogenic, stromal and oncogenic receptor TKs, prolonged progression free survival (PFS) versus placebo (PBO) across all regions/subgroups in the INTEGRATE phase 2 randomised trial (JCO 2016 43(23):2728-2735). IIa was designed to examine if Rego improves overall (OS). Methods: Double-blind placebo-controlled 3 comparing + best supportive...
Abstract Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, oncogenic receptor kinases. 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). 80 in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO)....
Abstract In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to in advanced, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) T790M mutation n = 47) by modulating selective pressure on resistant clones. The primary endpoint is progression free-survival (PFS) rate at 12 months, secondary endpoints include: feasibility therapy, overall response (ORR), survival...
There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab chEmotherapy as first-line treAtment advanced Mesothelioma (DREAM) Phase II multicenter study of anti-PD-L1, durvalumab, combination cisplatin pemetrexed the treatment unresectable malignant (PrE0505)] programmed death ligand-1 (PD-L1) inhibitor durvalumab standard exceeded prespecified safety...
To determine the activity and safety of lutetium-177 (177 Lu)-prostate-specific membrane antigen (PSMA)-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk early progression, to identify potential prognostic predictive biomarkers from imaging, blood tissue.ENZA-p (ANZUP 1901) is an open-label, randomized, two-arm, multicentre, phase 2 trial. Participants randomly assigned (1:1) treatment enzalutamide 160 mg daily alone or plus...
Abstract Background There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented prior trials. The NUTMEG study evaluated combination of nivolumab and temozolomide patients with aged 65 years older. Methods was a multicenter 2:1 randomized phase II trial for newly diagnosed experimental arm consisted hypofractionated chemoradiation temozolomide, then adjuvant temozolomide. standard primary objective improve overall survival...
728 Background: Gemcitabine (GEM) plus nab-paclitaxel (NAB-PAC) is a standard first-line chemotherapy regimen for advanced/metastatic pancreatic ductal adenocarcinoma (PDAC), with median Progression Free Survival (mPFS) and Overall (mOS) of 5.5 & 8.7 in the MPACT trial 5.6 9.2 months (mo) NAPOLI 3 trial, respectively. Certepetide (formerly LSTA1 or CEND-1) novel cyclic peptide that improves targeted penetration co-administered drugs into tumor stroma, leading to potentially increased...
Introduction All grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling then matching them best available drug based on their profile, maximising chances patient benefit while simultaneously testing multiple novel drugs. Methods analysis Low & Anaplastic Grade Glioma Umbrella Study MOlecular Guided TherapieS (LUMOS-2) will be an international,...